COAGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Hemab Therapeutics Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$32.09+2.02 (+6.72%)
Close on Oct 19, 2026
- Market cap
- $966.27M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.91 (−5.62%)since May 1, 2026
Weekly closes, adjusted for splits, on a log scale. Drag across the chart to measure a change.
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $966.27M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.13
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Book value per share
- $15.09
- Diluted shares
- 30M